Dhatri Kodali is an Oncology physician. OpenAlex indexes 28 publications with 200 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
47 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20254 payments
- Merck Sharp & Dohme LLCProgram year20252 payments
- Eisai Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
49.5%Erythropoiesis-stimulating Agent34.5%Darbepoetin alfa100%Part B, office-administered≥25 patientsParenteral Iron Replacement14.6%Iron sucrose100%Part B, office-administered≥12 patients+ 2 more classes in this area
Cancer & immunology
22.2%PD-1 inhibitor20.8%Pembrolizumab100%Part B, office-administered≥15 patientsAromatase Inhibitor0.8%Anastrozole54%Letrozole41%Exemestane5%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
19.4%Other antiemetics17.9%Fosaprepitant100%Part B, office-administered≥20 patientsSerotonin-3 Receptor Antagonist1.3%Palonosetron hcl96%Ondansetron Hcl4%Part D + Part B≥20 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Delayed-onset vitiligo in metastatic HR+/HER2– breast cancer during long-term ribociclib therapy.
European Journal of Case Reports in Internal Medicine
2025 - Neoadjuvant chemotherapy use trends among older women with breast cancer: 2010–2017
Breast Cancer Research and Treatment
2022 - Germline testing in community oncology patients with somatic BRCA1/2 mutations.
Journal of Clinical Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”